Lemboraxant is a novel dual orexin receptor antagonist specifically used to treat insomnia characterized by difficulty falling asleep or maintaining sleep. This drug helps restore normal sleep rhythm by inhibiting the wakefulness promoting effect of appetite suppressants. It was approved by the FDA in 2019 and approved for market in China in 2025.

1 Indications

(1) Treating insomnia: suitable for adult patients with symptoms of difficulty falling asleep or maintaining sleep, improving sleep quality by regulating awakening signals.

2. Mechanism of action

(1) Target effect: Competitive binding of orexin receptors OX1R and OX2R, blocking orexin neurotransmission and reducing arousal signals.

(2) Pharmacological characteristics: By inhibiting the wakefulness promoting effect and increasing drowsiness, it does not rely on the GABA system and has more precise sleep regulation functions.

3 Drug Characteristics

(1) Dosage form specifications: Three types of film coated tablets, 2.5mg, 5mg, and 10mg, are available in light red, light yellow, and orange colors, respectively.

(2) Product Name: The international market product name is Dayvigo, and the common name is lemborexant.

4 Precautions

(1) Daytime functional impact: may lead to drowsiness and increased risk of falls, and driving or operating machinery should be avoided.

(2) Special symptoms: May cause sleep paralysis, hallucinations, and complex sleep behaviors, requiring close monitoring.

(3) Respiratory function: Patients with respiratory disorders should carefully evaluate the risks when using it.